Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice

Trastuzumab prolongs progression-free and overall survival in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer. However, trastuzumab treatment is hampered by cardiotoxicity, defined as a left ventricular ejection fraction (LVEF) decline with a reported incidence r...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouwer, Nathalie I., Jager, Agnes, Liesting, Crista, Kofflard, Marcel J.M., Brugts, Jasper J., Kitzen, Jos J.E.M., Boersma, Eric, Levin, Mark-David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375662/
https://www.ncbi.nlm.nih.gov/pubmed/32361151
http://dx.doi.org/10.1016/j.breast.2020.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375662/
https://www.ncbi.nlm.nih.gov/pubmed/32361151
http://dx.doi.org/10.1016/j.breast.2020.04.005

Ejemplares similares